Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Dr. O'Neil on Emerging Therapeutic Techniques in Bladder Cancer

July 20th 2018

Brock O’Neil, MD, assistant professor, Division of Urology, University of Utah School of Medicine, Huntsman Cancer Institute, discusses emerging therapeutic techniques in bladder cancer.

Dr. Markman on Latest Advances in Treatment of Gynecological Malignancies

July 18th 2018

Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, discusses the latest advances in treatment for gynecological malignancies and other tumor types.

Dr. Agarwal on Frontline Treatment in Kidney Cancer

July 18th 2018

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses his preferred frontline treatment for patients with kidney cancer.

Galsky Discusses Ongoing Combination Immunotherapy Trials in Bladder Cancer

July 13th 2018

Matthew Galsky, MD, discusses the IMvigor130 and CheckMate-901 studies, as well as the future for chemotherapy in bladder cancer.

Dr. Van Veldhuizen on the Combination of Atezolizumab and Bevacizumab in Kidney Cancer

July 13th 2018

Peter J. Van Veldhuizen, MD, hematologist/oncologist, Sarah Cannon Research Institute, discusses the frontline combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) in the treatment of patients with kidney cancer.

Drake Discusses CARMENA Trial and Emerging Approaches in RCC

July 13th 2018

Charles G. Drake, MD, PhD, discusses the importance of the CARMENA results, the future of cytoreductive nephrectomy, and how the use of immunotherapy could change treatment in this setting.

Evolving Treatment Landscape of Renal Cell Carcinoma

July 11th 2018

Considerations for Using Adjuvant Therapy in mRCC

July 11th 2018

Sequencing Approaches in Metastatic Renal Cell Carcinoma

July 11th 2018

Disease Progression in Patients with Metastatic RCC

July 11th 2018

Sunitinib 4/2 vs 2/1 Schedule for Patients with mRCC

July 11th 2018

VEGF TKI + Immunotherapy Combinations for mRCC

July 11th 2018

Deferred Therapy for Favorable-Risk mRCC Patients

July 11th 2018

Selecting Immunotherapy versus VEGF TKI for mRCC

July 11th 2018

Risk Stratification for Metastatic Renal Cell Carcinoma

July 11th 2018

mRCC: Cytoreductive Nephrectomy in the Modern Era

July 11th 2018

mRCC Patient Selection for Ipilimumab/Nivolumab

July 11th 2018

Newly Diagnosed Metastatic Renal Cell Carcinoma

July 11th 2018

Dr. Gupta on Impact of Pembrolizumab Plus Bevacizumab Findings in RCC

July 10th 2018

Shilpa Gupta, MD, assistant professor of medicine, Hematology/Oncology and Transplantation Division, University of Minnesota, discusses the impact of the phase Ib/II results of pembrolizumab (Keytruda) plus bevacizumab (Avastin) in patients with metastatic renal cell carcinoma.

Localized Bladder Cancer Paradigm Still Faces Obstacles

July 9th 2018

Brock O’Neil, MD, discusses the struggles with treating localized bladder cancer in both the neoadjuvant and adjuvant settings, as well as the advancements with robotic cystectomy.